Organisation paid for research Program year 2023 Source: CMS Open Payments

New Jersey Urology, LLC

Neither a doctor nor a teaching hospital

Research payments

$133,411

100 payments

Through program year 2023, New Jersey Urology, LLC is reported as receiving $133,411 in research payments, across 100 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$7,533	35
2022	Research	$51,836	34
2021	Research	$65,030	29
2020	Research	$7,885	1
2019	Research	$1,126	1

Breakdown

Who paid Research payments · program years 2019–2023

Urogen Pharma, Inc. $96,276 92 payments
QED Therapeutics, Inc. $18,000 2 payments
AstraZeneca Pharmaceuticals LP $10,524 4 payments
Calyxo, Inc. $8,500 1 payment
Medtronic, Inc. $111 1 payment

Studies the money was for Research payments · program years 2019–2023

Urogen Bl-006 $79,706 35 payments
Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations $18,000 2 payments
A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and Locally Advanced Urothelial Carcinoma Study (mUC) $10,524 4 payments
Aspire $8,500 1 payment
Bl006 - A Phase 3 Study of Ugn-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (Atlas) $6,967 33 payments
Urogen Pharma Bl011 $5,243 5 payments
Urogen Bl006 $3,904 18 payments
Bl011 - A Phase 3 Single-Arm Study of Ugn -102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (Envision) $455 1 payment
Titan 2 $111 1 payment

What the money was spent on Research payments · program years 2019–2023

Patient care $18,000 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.